Small Molecule Drug Screening Service

Target-Based Screening

Our HTS platform incorporates target-based screening assays utilizing purified proteins, enabling the identification of compounds that modulate critical pathways involved in bladder cancer progression. By focusing on specific protein functions, we expedite the discovery of potential therapeutic agents.

Mechanism-Based Screening

Employing mechanism-informed phenotypic screening approaches, we bridge the gap between target-based and true phenotypic drug discovery. Through innovative cell-based assays that directly inform target engagement or modulation, we enhance the efficiency and relevance of drug screening efforts.

Phenotypic-Based Screening

Our service includes phenotypic-based screening assays, which assess the activity of compounds against bladder cancer cells without prior knowledge of the underlying mechanisms. By evaluating cellular responses and target engagement, we identify promising candidates with diverse mechanisms of action.

Cell-Based Screening

Recognizing the heterogeneity of bladder cancer, we offer screening services using patient-derived cells to better mimic the tumor microenvironment and individual patient responses. By culturing primary tumor cells obtained directly from patients, we facilitate the screening of potential therapeutics in a clinically relevant context.

Model-Based Screening

To recapitulate the complex three-dimensional architecture of bladder tumors, we employ advanced tumor models such as spheroids and organoids. These models better mimic the physiological conditions of bladder cancer, including hypoxia and heterogeneous cell populations.

Combination Screening

Bladder cancer treatment often involves combination chemotherapy, making the identification of synergistic drug combinations crucial. Our screening service employs sophisticated combination screening assays to evaluate the efficacy of drug pairs in inhibiting bladder cancer cell growth.